Terence Flynn
Stock Analyst at Morgan Stanley
(3.89)
# 656
Out of 4,989 analysts
201
Total ratings
59.22%
Success rate
7.31%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintains: Overweight | $23 → $22 | $4.08 | +439.22% | 2 | Aug 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $63 → $54 | $13.62 | +296.48% | 3 | Aug 12, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $32 → $33 | $23.86 | +38.31% | 18 | Aug 6, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $330 → $333 | $276.52 | +20.43% | 9 | Aug 6, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $255 | $219.68 | +16.08% | 18 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $171 → $176 | $177.16 | -0.65% | 23 | Jul 17, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $17 → $16 | $8.36 | +91.39% | 5 | Jul 15, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $51 → $54 | $35.50 | +52.13% | 12 | Jul 10, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $99 → $98 | $78.54 | +24.78% | 17 | Jul 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $34 | $43.89 | -22.52% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $132 → $133 | $98.31 | +35.29% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,133 → $1,135 | $726.58 | +56.21% | 20 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $348 → $328 | $429.79 | -23.68% | 10 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $7.71 | +42.67% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $12.61 | +74.46% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $10.23 | -2.25% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $61.07 | -47.60% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $17.19 | -35.99% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $25.57 | +361.48% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.40 | +234.03% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $139.00 | +213.67% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $455.30 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.20 | - | 1 | Jul 21, 2017 |
Alumis
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $4.08
Upside: +439.22%
Biohaven
Aug 12, 2025
Maintains: Overweight
Price Target: $63 → $54
Current: $13.62
Upside: +296.48%
Pfizer
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $32 → $33
Current: $23.86
Upside: +38.31%
Amgen
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $330 → $333
Current: $276.52
Upside: +20.43%
AbbVie
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $219.68
Upside: +16.08%
Johnson & Johnson
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $171 → $176
Current: $177.16
Upside: -0.65%
Nurix Therapeutics
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $8.36
Upside: +91.39%
Royalty Pharma
Jul 10, 2025
Maintains: Overweight
Price Target: $51 → $54
Current: $35.50
Upside: +52.13%
Merck & Co.
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $99 → $98
Current: $78.54
Upside: +24.78%
Bristol-Myers Squibb Company
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $43.89
Upside: -22.52%
Jul 10, 2025
Maintains: Overweight
Price Target: $132 → $133
Current: $98.31
Upside: +35.29%
Jul 10, 2025
Maintains: Overweight
Price Target: $1,133 → $1,135
Current: $726.58
Upside: +56.21%
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $348 → $328
Current: $429.79
Upside: -23.68%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $7.71
Upside: +42.67%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $12.61
Upside: +74.46%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $10.23
Upside: -2.25%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $61.07
Upside: -47.60%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $17.19
Upside: -35.99%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $25.57
Upside: +361.48%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.40
Upside: +234.03%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $139.00
Upside: +213.67%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $455.30
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $12.20
Upside: -